FDA Drafts New Rules for Testing Vaccine Shelf Life and Stability
Published Date: 6/24/2025
Notice
Summary
The FDA just released a draft guide to help drug makers test how long their medicines stay good and safe. This new guide updates old rules and adds advice for tricky products like vaccines and advanced therapies. Drug companies should get ready to follow these clearer, science-backed steps, which could speed up approvals and save money in the long run.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Consolidated Stability Testing Guidance
The FDA released a draft guidance called “Q1 Stability Testing of Drug Substances and Drug Products” that consolidates prior ICH stability guidances Q1A(R2), Q1B, Q1C, Q1D, Q1E, and Q5C (published November 2003; March 1996; May 1997; January 2003; June 2004; and July 1996). The draft guidance outlines stability data expectations to support drug product marketing, marketing authorization applications, and, where applicable, drug master files.
New Guidance for Vaccines and Advanced Therapies
The revision adds stability-related guidance for product categories that were not previously covered, including advanced therapy medicinal products, vaccines, and other complex biological products including combination products. Companies working with these product types now have stability testing guidance included in this draft.
Internationally Harmonized, Flexible Testing Approach
The draft guidance, prepared under the International Council for Harmonisation (ICH), is intended to provide an internationally harmonized approach to conducting and presenting stability testing data. It also states that alternative, scientifically justified approaches may be used when warranted by scientific considerations and the characteristics of the data being evaluated.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Previous / Next Documents
Previous: 2025-11551 — Process Safety Management of Highly Hazardous Chemicals Standard; Extension of the Office of Management and Budget's (OMB) Approval of Information Collection (Paperwork) Requirements
OSHA is asking for public feedback to keep collecting important safety info about handling dangerous chemicals. This extension means companies must keep following the rules without any new costs or changes right now. It helps make sure everyone stays safe while working with hazardous stuff.
Next: 2025-11553 — Importer of Controlled Substances Application: Arizona Department of Corrections
The Arizona Department of Corrections wants to officially import certain controlled substances. This means they’ll be able to bring in these drugs legally for their work, following all the rules. If approved, this could affect how they manage medications and security, with no extra costs mentioned yet.